There was bittersweet news for people affected by Parkinson’s disease (PD) on Monday, as San Diego-based Neurocrine Biosciences (Nasdaq: NBIX) scored approval for Ongentys (opicapone), but confirmed it would delay launch while the COVID-19 pandemic rages.
The novel COMT inhibitor was approved by the Food and Drug Administration in the USA as an add-on treatment to levodopa/carbidopa, for people experiencing "off" episodes.
As PD progresses, people taking levodopa/carbidopa may begin to experience more and longer periods between treatment doses, where symptoms can recur. Ongentys helps increase the “on” time where symptoms are controlled.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze